NASDAQ:CPIX Cumberland Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.10 +0.09 (+4.48%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$2.05▼$2.1450-Day Range$1.93▼$2.7052-Week Range$1.89▼$7.51Volume2,704 shsAverage Volume69,939 shsMarket Capitalization$31.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPIX Stock Forecast (MarketRank)Overall MarketRank™1.56 out of 5 starsMedical Sector987th out of 1,418 stocksPharmaceutical Preparations Industry494th out of 679 stocksAnalyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cumberland Pharmaceuticals. Previous Next 3.9 Community Rank Outperform VotesCumberland Pharmaceuticals has received 187 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCumberland Pharmaceuticals has received 138 “underperform” votes. (Add your “underperform” vote.)Community SentimentCumberland Pharmaceuticals has received 57.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote “Outperform” if you believe CPIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,564.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders43.55% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.11% of the stock of Cumberland Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cumberland Pharmaceuticals (NASDAQ:CPIX)Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More CPIX Stock News HeadlinesJune 24, 2022 | msn.comReport: Body recovered near edge of Cumberland RiverJune 24, 2022 | msn.comCumberland County Prison inmate accused of biting corrections officerJune 23, 2022 | msn.comCumberland County adds 187 acres of preserved farmland, marks 200th preserved farm since 1989June 23, 2022 | msn.comCumberland man guilty of murder sentenced in Barron County CourtJune 23, 2022 | msn.comCumberland Co. warns: Scammers conning community into thinking it has criminal chargesJune 23, 2022 | msn.comFayetteville, Cumberland OK $827K in incentives to lure homebuilding company, 189 jobsJune 23, 2022 | americanbankingnews.comCumberland Pharmaceuticals (NASDAQ:CPIX) Earns Hold Rating from Analysts at StockNews.comJune 22, 2022 | msn.comCumberland County Sheriffs searching for suspects who stole generator from middle schoolJune 22, 2022 | msn.com149 Cumberland County residents died from overdoses in 2020. Here's how your ideas can helpJune 22, 2022 | msn.comVirginia lawmakers want Cumberland dog breeder’s license suspended to prevent sale of beaglesJune 22, 2022 | msn.comTwo People Shot Dead in Cumberland, Rhode IslandJune 22, 2022 | msn.comPolice respond to home in CumberlandJune 21, 2022 | msn.comKUB: Church Ave. and Cumberland Ave. to close overnight for electric workSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CPIX CUSIP23077010 CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees83Year Founded1999Company Calendar Last Earnings5/10/2022Today6/24/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3.51 million Net Margins-13.81% Pretax Margin-18.06% Return on Equity-5.57% Return on Assets-2.77% Debt Debt-to-Equity Ratio0.49 Current Ratio1.85 Quick Ratio1.44 Sales & Book Value Annual Sales$35.99 million Price / Sales0.86 Cash Flow$0.31 per share Price / Cash Flow6.68 Book Value$2.88 per share Price / Book0.73Miscellaneous Outstanding Shares14,766,000Free Float8,335,000Market Cap$31.01 million OptionableOptionable Beta0.31 Social Links Cumberland Pharmaceuticals Frequently Asked Questions How has Cumberland Pharmaceuticals' stock price performed in 2022? Cumberland Pharmaceuticals' stock was trading at $4.67 at the beginning of 2022. Since then, CPIX stock has decreased by 55.0% and is now trading at $2.10. View the best growth stocks for 2022 here. When is Cumberland Pharmaceuticals' next earnings date? Cumberland Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Cumberland Pharmaceuticals. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $11.18 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 13.81% and a negative trailing twelve-month return on equity of 5.57%. View Cumberland Pharmaceuticals' earnings history. Who are Cumberland Pharmaceuticals' key executives? Cumberland Pharmaceuticals' management team includes the following people: Mr. A. J. Kazimi MBA, Founder, Chairman, Pres & CEO (Age 64, Pay $872.63k)Mr. John Michael Hamm, Sr. Director of Fin. & Accounting and CFO (Age 65, Pay $304.91k)Mr. Leo B. Pavliv R.Ph., Exec. VP of Operations & Chief Devel. Officer (Age 61, Pay $505.74k)Mr. James Lowrance Herman, Exec. VP of National Accounts & Chief Compliance Officer (Age 67, Pay $320.65k)Ms. Jean W. Marstiller, Sr. VP of Admin. Services & Corp. Sec. (Age 72)Ms. Cindy B. Patton, Sr. Director of Field Marketing (Age 69)Mr. Adam S. Mostafa, Managing Director (Age 42)Mr. Todd M. Anthony, VP of Organizational Devel.Ms. Erin Smith Gull, Sr. Corp. Relations Associate What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO? 9 employees have rated Cumberland Pharmaceuticals CEO A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among Cumberland Pharmaceuticals' employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Cumberland Pharmaceuticals' key competitors? Some companies that are related to Cumberland Pharmaceuticals include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Nektar Therapeutics (NKTR). View all of CPIX's competitors. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), CorMedix (CRMD) and Xeris Biopharma (XERS). What is Cumberland Pharmaceuticals' stock symbol? Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX." Who are Cumberland Pharmaceuticals' major shareholders? Cumberland Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.34%), Dimensional Fund Advisors LP (4.27%), Vanguard Group Inc. (2.55%), Acadian Asset Management LLC (1.27%), State Street Corp (0.28%) and M Holdings Securities Inc. (0.07%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, A J Kazimi, Caroline Young, Gordon R Bernard, Joseph C Galante, Kenneth Krogulski, Martin E Cearnal, Martin E Cearnal and William Sumas. View institutional ownership trends for Cumberland Pharmaceuticals. Which institutional investors are selling Cumberland Pharmaceuticals stock? CPIX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, and Vanguard Group Inc.. View insider buying and selling activity for Cumberland Pharmaceuticals or view top insider-selling stocks. Which institutional investors are buying Cumberland Pharmaceuticals stock? CPIX stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, and M Holdings Securities Inc.. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joseph C Galante, Kenneth Krogulski, and Martin E Cearnal. View insider buying and selling activity for Cumberland Pharmaceuticals or or view top insider-buying stocks. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cumberland Pharmaceuticals' stock price today? One share of CPIX stock can currently be purchased for approximately $2.10. How much money does Cumberland Pharmaceuticals make? Cumberland Pharmaceuticals (NASDAQ:CPIX) has a market capitalization of $31.01 million and generates $35.99 million in revenue each year. The specialty pharmaceutical company earns $-3.51 million in net income (profit) each year or ($0.34) on an earnings per share basis. How many employees does Cumberland Pharmaceuticals have? Cumberland Pharmaceuticals employs 83 workers across the globe. When was Cumberland Pharmaceuticals founded? Cumberland Pharmaceuticals was founded in 1999. How can I contact Cumberland Pharmaceuticals? Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com. The specialty pharmaceutical company can be reached via phone at (615) 255-0068, via email at [email protected], or via fax at 615-255-0094. This page (NASDAQ:CPIX) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
